Biomerica signs USD 500,000 secured promissory note with CEO-affiliated buyers at 8% interest
Biomerica, Inc. BMRA | 0.00 |
- Biomerica entered a $500,000 secured promissory term note on May 29, 2026, tied to a planned sale of Diagnosis S.A. shares.
- The note carries 8% annual interest, matures 12 months from the effective date, secured by a lien on 78,750 Diagnosis shares.
- Principal and accrued interest are payable at maturity, subject to forgiveness beyond 60 days’ interest once the share transfer closes.
- The buyers are affiliated with Chief Executive Officer Zackary Irani; closing depends on required Polish regulatory approvals expected within 30 days.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomerica Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-027290), on June 04, 2026, and is solely responsible for the information contained therein.
